Guanfacine to Improve Substance Use Outcomes in Women
Status:
Recruiting
Trial end date:
2023-03-31
Target enrollment:
Participant gender:
Summary
Hypothesis: Guanfacine (GUA) (3mg/day) will reduce drug craving, improve cognitive
flexibility and result in associated lower drug use in women with substance use disorder
(SUD) in an outpatient clinical setting.